Preview

Russian Journal of Transplantology and Artificial Organs

Advanced search

De novo hepatitis B virus infection after liver transplantation

https://doi.org/10.15825/1995-1191-2022-3-37-41

Abstract

De novo hepatitis B virus (HBV) infection developing after liver transplantation (LTx) is the development of infection in a patient with liver disease etiologically unrelated to HBV infection and who had no preoperative HBV markers. Objective: to analyze the clinical features and characteristics of de novo HBV infection and evaluate the efficacy of nucleos(t)ide analogue therapy in liver transplant recipients. Materials and methods. The study involved 247 adult patients who underwent deceased donor LTx from 2016 to 2022 at Shumakov National Medical Research Center of Transplantology and Artificial Organs and who had no pre-transplant HBV markers. Results. Twenty-two (7%) of 247 patients had de novo HBV markers from 5 to 69 months. At the time HBV DNA was detected, the mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in the patients was 53.3 ± 36.4 IU/L and 54.5 ± 33.0 IU/L, respectively. All patients received nucleos(t)ide analogues (NAs). The therapy led to a statistically significant decrease in the mean ALT level to 31.5 ± 24.2 IU/L (p = 0.049)

About the Authors

A. D. Nikogosova
Shumakov National Medical Research Center of Transplantology and Artificial Organs
Russian Federation

Anna Nikogosova

Address: 1, Shchukinskaya str., Moscow, 123182
Phone: (958) 828-32-09



D. V. Umrik
Shumakov National Medical Research Center of Transplantology and Artificial Organs
Russian Federation

Moscow



O. M. Tsirulnikova
Shumakov National Medical Research Center of Transplantology and Artificial Organs; Sechenov University
Russian Federation

Moscow



References

1. Castells L, Vargas V, Rodríguez F, Allende H, Buti M, Sánchez-Avila JF et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl. 2002; 8 (10): 892– 900.

2. Nugroho A, Lee KW, Kim H, Yi NJ, Suh KS. De novo Hepatitis B Virus Infection After Liver Transplantation in Hepatitis B Core-positive Recipients Using Hepatitis B Core-negative Grafts. Transplant Proc. 2019; 51 (3): 842–844.

3. Verna EC. Updated Hepatitis B Guidance: Implications for liver transplant patients. Liver Transplant. 2018; 24 (4): 465–469.

4. Jung H-S, Choi Y, Yoon KC, Hong SY, Suh S, Hong K et al. Hepatitis B immunoglobulin prophylaxis for de novo hepatitis B infection in liver transplantation: a 30- year experience. Ann Transl Med. 2022; 10 (5): 243.

5. Wang SH, Loh PY, Lin TL, Lin LM, Li WF, Lin YH et al. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft. Liver Transpl. 2017; 23 (10): 1266–1272.

6. Hornuss D, Rudi A, Koerner L, Mohr I, Merle U, Wehling C et al. HBV-infection rate and long-term outcome after liver-transplantation of anti-HBc-positive livergrafts to HBV-naïve recipients: A retrospective study. Clin Res Hepatol Gastroenterol. 2021; 45 (2): 101496.

7. Riveiro-Barciela M. Outcome and risk of de novo Hepatitis B after liver transplantation: Are all anti-HBc-positive grafts the same? Clin Res Hepatol Gastroenterol. 2020; 44 (6): 791–793.

8. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67 (4): 1560–1599.

9. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: A systematic review. J Hepatol. 2010; 52 (2): 272–279.

10. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007; 46 (1): 254–265.

11. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012; 56 (Suppl 1): S112–S122.

12. Katz LH, Tur-Kaspa R, Guy DG, Paul M. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Cochrane database Syst Rev. 2010. 7 (7): CD006005.

13. Wong TC, Fung JY, Cui TY, Lam AH, Dai JW, Chan AC et al. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis. J Hepatol. 2019; 70 (6): 1114–1122.

14. Ossami Saidy RR, Eurich F, Postel MP, Dobrindt EM, Feldkamp J, Schaper SJ et al. Clinical and Histological Long-Term Follow-Up of De novo HBV-Infection after Liver Transplantation. Medicina (Kaunas). 2021; 57 (8): 767.


Review

For citations:


Nikogosova A.D., Umrik D.V., Tsirulnikova O.M. De novo hepatitis B virus infection after liver transplantation. Russian Journal of Transplantology and Artificial Organs. 2022;24(3):37-41. https://doi.org/10.15825/1995-1191-2022-3-37-41

Views: 753


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1995-1191 (Print)